In ovarian cancer, CXCR6 is highly expressed on TRM‐like cells, and its ligand CXCL16, primarily produced by EpCAM−CD45− stromal cells, facilitates their spatial retention within the tumor microenvironment, suggesting that CXCL16 delivery or CXCR6 engineering may promote TRM accumulation [33]. This evidence concerns the gene CXCL16 and neoplasm.